BOSTON & GENEVA--(BUSINESS WIRE)--PHT Corporation, the leading provider of technologies used to collect patient-driven eData for clinical research, will join Celgene Corporation to present a new educational webinar to offer real-world experiences on the business and science benefits of adopting eCOA (electronic clinical outcome assessment) systems to collect and report on compliant patient data in clinical trials.
Date: Thursday, 30 October 2014
Time: 11am EDT (NA) / 3pm GMT (UK) / 4pm CET (EU-Central)
Duration: 90 minutes
The webinar will examine three key benefits of eCOAs: (1) reduced data variance, (2) increased patient compliance, and (3) reduced site monitoring costs.
Webinar co-presenter Valdo Arnera MD, General Manager of PHT Europe, explained, “The cost of the average drug developed by a major pharmaceutical company is approaching $4 billion [almost €3 billion]. PHT experience on more than 675 global trials indicates patients who use electronic methods of data collection instead of paper exceed average compliance rates, which can speed the go/no-go decision for new drugs.”
Attendees will hear lessons learned, experience gained from real-world trials collecting eCOA data including Celgene’s experience using the PHT SitePad® System to collect key clinician data and patient reported outcomes (PROs) for a recently approved oral drug for psoriasis and psoriatic arthritis which was approved by the FDA this year.
Presenters will discuss industry trends, research and best practices in eCOA including regulatory mandates and recommendations; eCOA case studies of increased compliance and data quality; comparisons of monitoring costs for eCOA vs. paper; and, a sponsor’s experience with eCOA adoption and ROI.
About the Presenters
Elisabeth Kurkimilis, Senior Manager of Clinical Operations, Celgene Corporation – Ms. Kurkimilis has over 25 years of experience in the pharmaceutical industry. Her therapeutic area experience includes anti-infectives, chronic and acute pain management, asthma, oncology, and inflammation and immunology. Ms. Kurkimilis is responsible for a 20-country, 2,000-subject Phase III Program of four trials in inflammation and immunology.
Valdo Arnera MD, General Manager Europe, PHT Corporation – Dr. Arnera is a physician, scientist and entrepreneur who has advanced pharmaceutical research for over 20 years. He received the SCRIP Journal Lifetime Achievement award and has been named to the PharmaVOICE 100. Previously Dr. Arnera founded the first European Central Clinical Laboratory, which became the Covance Central Laboratory, and practiced medicine. He has published several articles and speaks frequently at industry events.
About PHT Corporation
PHT Corporation is the eClinical innovator leading the adoption of patient-driven mobile apps for better clinical research. The PHT electronic clinical outcome assessment (eCOA) system collects and reports secure real-time patient data from the latest mobile devices. PHT scientific, regulatory and technological expertise combined with quality outcomes data enable clients to make research decisions with confidence. Sponsors and CROs have leveraged the PHT Patient Suite in 675+ trials resulting in 19+ regulatory approvals. Visit phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Facebook, Twitter, Google+ and YouTube.